Tessier-Lavigne Marc
Known title: DirectorCIK: 0001437435
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Transaction History
| DNLI | ▲ Buy | Grant | 6,037 | $0 | 6/3/2025 | View on chart |
| DNLI | ▲ Buy | Grant | 5,967 | $0 | 5/31/2024 | View on chart |
| DNLI | ▲ Buy | Grant | 4,216 | $0 | 6/1/2023 | View on chart |
| REGN | ▲ Buy | Grant | 165 | $0 | 1/3/2023 | View on chart |
| REGN | ▲ Buy | Grant | 165 | $0 | 1/3/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 20,000 | $610K | 11/23/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 11,252 | $341K | 11/2/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 8,748 | $264K | 11/1/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,612 | $1.5M | 10/3/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 3,612 | $2.6M | 10/3/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,428 | $1.4M | 9/30/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 3,428 | $2.4M | 9/30/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,798 | $1.6M | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 637 | $439K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 16 | $11K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 321 | $221K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,009 | $696K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 692 | $478K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 554 | $383K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 85 | $59K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 160 | $112K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 208 | $145K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 80 | $56K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 16 | $11K | 9/29/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 20 | $14K | 9/29/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 15,577 | $479K | 9/28/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 4,423 | $137K | 9/28/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 19,900 | $629K | 8/23/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 100 | $3K | 8/23/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 19,800 | $705K | 7/25/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 200 | $7K | 7/25/2022 | View on chart |
| DNLI | ▼ Sell | Other | 6,766 | $210K | 6/24/2022 | View on chart |
| DNLI | ▼ Sell | Other | 39,984 | $1.2M | 6/24/2022 | View on chart |
| DNLI | ▼ Sell | Other | 13,250 | $412K | 6/23/2022 | View on chart |
| DNLI | ▲ Buy | Grant | 5,986 | $0 | 6/2/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 8,402 | $281K | 3/23/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 11,598 | $396K | 3/23/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 7,439 | $2.8M | 3/21/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 7,439 | $5.1M | 3/21/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 7,830 | $2.9M | 3/17/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 7,830 | $5.3M | 3/17/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 4,361 | $2.9M | 3/16/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 4,361 | $1.6M | 3/16/2022 | View on chart |
| REGN | ▲ Buy | Grant | 191 | $0 | 1/3/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 3,343 | $151K | 12/30/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 900 | $41K | 12/30/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 800 | $37K | 12/30/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 3,377 | $154K | 12/30/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 5,625 | $255K | 12/30/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 6,002 | $272K | 12/30/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 10,700 | $470K | 12/29/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 10,700 | $469K | 12/29/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 10,704 | $470K | 12/29/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 3,732 | $166K | 12/28/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 3,602 | $160K | 12/28/2021 | View on chart |
| DNLI | ▼ Sell | Open Market | 3,646 | $162K | 12/28/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,784 | $1.4M | 12/9/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 3,784 | $2.5M | 12/9/2021 | View on chart |
| DNLI | ▼ Sell | Gift | 100,000 | $0 | 10/4/2021 | View on chart |
| DNLI | ▼ Sell | Gift | 300,000 | $0 | 10/4/2021 | View on chart |
| DNLI | ▼ Sell | Gift | 100,000 | $0 | 10/4/2021 | View on chart |
| DNLI | ▼ Sell | Gift | 100,000 | $0 | 10/4/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,260 | $806K | 9/13/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 4,250 | $1.2M | 9/13/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 4,250 | $1.2M | 9/13/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 4,250 | $1.2M | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 816 | $519K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 816 | $520K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 2,098 | $1.3M | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 981 | $628K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 952 | $611K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,645 | $1.1M | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,549 | $997K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 844 | $544K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 61 | $39K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 354 | $229K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 425 | $275K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 381 | $247K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 124 | $81K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 56 | $36K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 249 | $162K | 9/13/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 139 | $91K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Denali Therapeutics Shares Test Fair Value Amid Pullback
Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.
Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.